Chlorisondamine
Chlorisondamine is a ganglionic blocker that is used primarily in research settings. It is a quaternary ammonium compound and acts as a competitive antagonist at nicotinic acetylcholine receptors (nAChRs) in the autonomic ganglia.
Mechanism of Action[edit]
Chlorisondamine works by inhibiting the transmission of nerve impulses in the autonomic nervous system. It binds to the nicotinic acetylcholine receptors at the ganglia, preventing the action of acetylcholine, a neurotransmitter responsible for the activation of these receptors. This results in the blockade of both sympathetic and parasympathetic outflow.
Uses[edit]
While Chlorisondamine is not commonly used in clinical practice, it is valuable in pharmacological research to study the role of nicotinic receptors in various physiological and pathological processes. It has been used in studies investigating hypertension, cardiovascular diseases, and neurodegenerative disorders.
Pharmacokinetics[edit]
As a quaternary ammonium compound, Chlorisondamine is poorly absorbed from the gastrointestinal tract and does not easily cross the blood-brain barrier. This limits its effects primarily to the peripheral nervous system.
Side Effects[edit]
Due to its action on the autonomic ganglia, Chlorisondamine can cause a range of side effects, including hypotension, tachycardia, dry mouth, constipation, and urinary retention. These side effects are a result of the blockade of autonomic ganglionic transmission.
Related Compounds[edit]
Chlorisondamine is related to other ganglionic blockers such as hexamethonium and mecamylamine. These compounds share a similar mechanism of action but differ in their chemical structure and pharmacokinetic properties.
History[edit]
Chlorisondamine was first synthesized in the mid-20th century and has since been used primarily in experimental settings. Its role in clinical medicine has been limited due to the availability of more selective agents for the treatment of autonomic disorders.
See Also[edit]
- Ganglionic blocker
- Nicotinic acetylcholine receptor
- Autonomic nervous system
- Hypertension
- Neurodegenerative disorders
References[edit]
External Links[edit]
-
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
